Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Beta DrugsNSE:BETA -4.62%90 EV-to-EBITDA is 26.46 as of Aug. 18, 2026, which is 0% below its 10-year median of 26.59. GuruFocus rates NSE:BETA with a GF Score™ of 90/100 and a GF Value™ of ₹2,691.18 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 734 Drug Manufacturers companies, Beta Drugs ranks worse than 75.75% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Beta Drugs's enterprise value is ₹24,634 Mil.
Beta Drugs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹931 Mil. Therefore, Beta Drugs's EV-to-EBITDA for today is 26.46.
The historical rank and industry rank for Beta Drugs's EV-to-EBITDA or its related term are showing as below:
NSE:BETA'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 9.57 Med: 26.59 Max: 110.17
Current: 26.45
During the past 13 years, the highest EV-to-EBITDA of Beta Drugs was 110.17. The lowest was 9.57. And the median was 26.59.
NSE:BETA's EV-to-EBITDA is ranked worse than 75.75% of 734
companies
in the Drug Manufacturers industry
Industry Median: 13.325
vs NSE:BETA: 26.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Beta Drugs's share price for today is ₹2432.90.
Beta Drugs's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹44.214.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Beta Drugs's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Beta Drugs's EV-to-EBITDA falls into.
Beta Drugs's current Enterprise Value is ₹24,634 Mil.
Beta Drugs's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹931 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beta Drugs (NSE:BETA) has a EV-to-EBITDA of 26.46 as of Aug. 18, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beta Drugs. This is near median its historical median of 26.59. Over the past decade, Beta Drugs' EV-to-EBITDA has ranged from 9.57 to 110.17. According to the industry distribution chart, Beta Drugs ranks #556 out of 734 companies in the Drug Manufacturers industry, placing it in the top 75.7%.
Is Beta Drugs' EV-to-EBITDA too high?
Beta Drugs' current EV-to-EBITDA of 26.46 is near median its 10-year median of 26.59. Over the past 10 years, this metric has ranged from a low of 9.57 to a high of 110.17. The Drug Manufacturers industry median EV-to-EBITDA is 13.33. Beta Drugs' value of 26.46 is 98.6% above this industry median. Based on the distribution chart, Beta Drugs ranks #556 out of 734 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beta Drugs has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #556 out of 734 companies for EV-to-EBITDA. This places Beta Drugs in the lower half of its industry. The industry median EV-to-EBITDA is 13.33. Beta Drugs' value of 26.46 is 98.6% above this benchmark. Historically, Beta Drugs' own EV-to-EBITDA has ranged from 9.57 to 110.17 over the past decade. While the company's 10-year median is 26.59 vs. the industry median of 13.33, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.33, based on 734 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current EV-to-EBITDA of 26.46 is 98.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Beta Drugs. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current EV-to-EBITDA is 26.46, which is near median its own 10-year median of 26.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹2,691.18, compared to a current price of ₹2,432.90 — trading 9.6% below its estimated fair value. The current EV-to-EBITDA is 26.46, which is near median its 10-year median of 26.59 and 98.6% above the Drug Manufacturers industry median of 13.33. Beta Drugs' overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current EV-to-EBITDA is 26.46 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be undervalued.
The current stock price of ₹2,432.90 is trading 9.6% below its estimated GF Value™ of ₹2,691.18.
GuruFocus considers Beta Drugs to be Modestly Undervalued.
Key valuation signals for NSE:BETA:
EV-to-EBITDA: 26.46 (near median its 10-year median of 26.59)
GF Value™: ₹2,691.18 vs. price of ₹2,432.90 (9.6% below fair value)
Industry Position: 98.6% above the Drug Manufacturers median (#556 of 734)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
90GF Score
Get the complete analysis for NSE:BETA
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
